Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 1/20 | 0.55 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.55 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.55 |
| ▸ | ATF1 | P18846 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PTGES | O14684 | 9/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19064507 | 1.00 | P2RX1 (0.55) | P2RX1P2RX4P2RX7TMPRSS4ATF1 | |
| SCHEMBL21645366 | 0.90 | PTGES (0.52) | TMPRSS4PTGES | |
| SCHEMBL30899214 | 0.90 | PTGES (0.52) | TMPRSS4PTGES | |
| SCHEMBL19083018 | 0.88 | P2RX1 (0.54) | P2RX1P2RX4P2RX7TMPRSS4ATF1 | |
| SCHEMBL21645628 | 0.87 | PTGES (0.54) | TMPRSS4ATF1NFKB1PTGESNPC1 | |
| SCHEMBL30899219 | 0.87 | PTGES (0.54) | TMPRSS4ATF1NFKB1PTGESNPC1 | |
| SCHEMBL21645373 | 0.86 | MAPT (0.47) | P2RX1P2RX4P2RX7NFKB1PTGES | |
| SCHEMBL30899218 | 0.86 | MAPT (0.47) | P2RX1P2RX4P2RX7NFKB1PTGES | |
| SCHEMBL23512180 | 0.82 | P2RX1 (0.55) | P2RX1P2RX4P2RX7TMPRSS4ATF1 | |
| SCHEMBL21645370 | 0.81 | ATF1 (0.48) | ATF1NFKB1PTGESJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024256607-A1 | STANDARDISING PLURIPOTENT STEM CELLS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-12-19 | — | — | WO | claimed |
| CN-114874973-A | Culture medium and culture method for obtaining mature hepatocytes | 深圳市三启生物技术有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | disclosed |
| CN-121731314-A | Application of DK419 and ZINC13466751 pharmaceutical composition in preparation of medicine for treating human viral lymphoma | 湖北江夏实验室 | 2026-03-27 | — | — | CN | disclosed |
| CN-121731314-A | Application of DK419 and ZINC13466751 pharmaceutical composition in preparation of medicine for treating human viral lymphoma | 湖北江夏实验室 | 2026-03-27 | — | — | CN | disclosed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | disclosed |
| CN-120549917-A | Application of small molecular compound DK419 in preparation of anti-staphylococcal infection drugs | 深圳市南山区人民医院 | 2025-08-29 | — | — | CN | disclosed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024256607-A1 | STANDARDISING PLURIPOTENT STEM CELLS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-12-19 | — | — | WO | disclosed |
| US-20240216372-A1 | THERAPEUTICS FOR KELOIDS AND OTHER FIBROTIC DISORDERS | NATIONAL INSTITUTES OF HEALTH | 2024-07-04 | — | — | US | disclosed |
| US-11987579-B2 | Niclosamide analogues and therapeutic use thereof | DUKE UNIVERSITY (US) | 2024-05-21 | — | — | US | disclosed |
| CN-114874973-B | Culture medium and culture method for obtaining mature hepatocytes | 深圳市三启生物技术有限公司 | 2023-03-21 | — | — | CN | disclosed |
| WO-2023282749-A1 | GENE CLASSIFIER FOR SPATIAL IMMUNE PHENOTYPES OF CANCER | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2023-01-12 | — | — | WO | disclosed |
| CN-114874973-A | Culture medium and culture method for obtaining mature hepatocytes | 深圳市三启生物技术有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-20220125807-A1 | PHARMACEUTICAL COMBINATION OF WNT SIGNALING AND MACC1 INHIBITORS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125807-A1 | PHARMACEUTICAL COMBINATION OF WNT SIGNALING AND MACC1 INHIBITORS | S100A4, CTNNBL1, CTNNB1 | P2RX1 3492/4885P2RX4 2150/4885P2RX7 3931/4885 |
| US-11987579-B2 | Niclosamide analogues and therapeutic use thereof | DNER, SFRP1, WNT1 | P2RX1 1606/4885P2RX4 1483/4885P2RX7 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.